Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal GM-CSF, fosfomycin, and metronidazole in uncomplicated appendicitis
2015-005772-16Phase 2Completed
- Sponsor
- Herlev Hospital
- Start
- Feb 2016
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of molgramostim, fosfomycin and metronidazole in appendicitis and peritonitis, sponsored by Herlev Hospital. Primary endpoint: Postoperative white blood cell count safety assessment. Started Feb 2016; status: completed.
02
Drugs
molgramostimfosfomycinmetronidazole
03
Conditions
appendicitisperitonitis
Beyond the preview
Go deeper on 2015-005772-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005772-16.